Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. - Shaw B; Chung E; Wellard C; Yoo E; Bennett R; Birks C; Johnston A; Cheah CY; Hamad N; Simpson J; Barraclough A; Ku M; et al. (EJHaem, 2024)